Table 1 Patient characteristics
| Â | No. (%) | |||
|---|---|---|---|---|
Characteristic | Diarrhea treated with immunosuppressants, n = 79 | Diarrhea without treatment, n = 38 | No diarrhea, n = 210 | P |
Mean age (years, SD) | 59.8 (15) | 62.2 (12) | 59.2 (14) | 0.480 |
Male sex | 53 (67) | 25 (66) | 133 (63) | 0.825 |
Race |  |  |  | < 0.001 |
 White | 75 (95) | 32 (84) | 154 (73) |  |
 Other | 4 (5) | 6 (16) | 56 (27) |  |
Comorbidities present | 24 (30) | 9 (24) | 62 (30) | 0.733 |
Underlying autoimmune disorder | 4 (5) | 1 (3) | 13 (6) | 0.663 |
History of smoking | 36 (46) | 20 (53) | 107 (51) | 0.671 |
History of use of nonsteroidal anti-inflammatory agents | 38 (48) | 15 (39) | 80 (38) | 0.300 |
ECOG performance status | Â | Â | Â | 0.070 |
 0–2 | 78 (99) | 38 (100) | 197 (94) |  |
 3–4 | 1 (1) | 0 (0) | 13 (6) |  |
Malignancy type |  |  |  | < 0.001 |
 Melanoma | 55 (70) | 9 (24) | 56 (27) |  |
 Solid tumor | 23 (29) | 14 (37) | 111 (53) |  |
 Hematologic | 1 (1) | 15 (39) | 43 (20) |  |
Cancer Stagea |  |  |  | < 0.001 |
 Stage III | 16 (21) | 2 (9) | 7 (4) |  |
 Stage IV | 61 (79) | 21 (91) | 149 (96) |  |
Colitis grade 2–3 | 49 (62) | – | – | – |
Checkpoint inhibitor type |  |  |  | < 0.001 |
 Ipilimumab | 48 (61) | 23 (61) | 67 (32) |  |
 Nivolumab | 5 (6) | 8 (21) | 87 (41) |  |
 Pembrolizumab | 13 (16) | 6 (16) | 50 (24) |  |
 Combinationb | 12 (15) | 1 (3) | 6 (3) |  |
 Atezolizumab | 1 (1) | 0 (0) | 0 (0) |  |